YU34296A - Use a compounds for medicament obtaining and pharmaceutical composition thereof - Google Patents

Use a compounds for medicament obtaining and pharmaceutical composition thereof

Info

Publication number
YU34296A
YU34296A YU34296A YU34296A YU34296A YU 34296 A YU34296 A YU 34296A YU 34296 A YU34296 A YU 34296A YU 34296 A YU34296 A YU 34296A YU 34296 A YU34296 A YU 34296A
Authority
YU
Yugoslavia
Prior art keywords
medicament
compounds
pyrrolidinyl
alkyl
obtaining
Prior art date
Application number
YU34296A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
Joseph Cullinan George
Anthony Fontana Steven
Sharon Lee Fuchs-Young Robin
Lawrence Glasebrook Andrew
Original Assignee
Eli Lilly And Company
Lilly Corporate Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company, Lilly Corporate Center filed Critical Eli Lilly And Company
Publication of YU34296A publication Critical patent/YU34296A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
YU34296A 1995-06-06 1996-06-05 Use a compounds for medicament obtaining and pharmaceutical composition thereof YU34296A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47111195A 1995-06-06 1995-06-06

Publications (1)

Publication Number Publication Date
YU34296A true YU34296A (en) 1999-11-22

Family

ID=23870302

Family Applications (1)

Application Number Title Priority Date Filing Date
YU34296A YU34296A (en) 1995-06-06 1996-06-05 Use a compounds for medicament obtaining and pharmaceutical composition thereof

Country Status (27)

Country Link
EP (1) EP0747056B1 (sr)
JP (1) JP2001501907A (sr)
KR (1) KR19990022497A (sr)
CN (1) CN1239429A (sr)
AR (2) AR003134A1 (sr)
AT (1) ATE187643T1 (sr)
AU (1) AU696927B2 (sr)
BR (1) BR9608390A (sr)
CA (1) CA2223174A1 (sr)
CO (1) CO4700447A1 (sr)
CZ (1) CZ383097A3 (sr)
DE (1) DE69605600T2 (sr)
DK (1) DK0747056T3 (sr)
EA (1) EA199800014A1 (sr)
ES (1) ES2142545T3 (sr)
GR (1) GR3032863T3 (sr)
HU (1) HUP9900854A3 (sr)
IL (1) IL118573A (sr)
NO (1) NO975560L (sr)
PE (1) PE2298A1 (sr)
PL (1) PL323941A1 (sr)
PT (1) PT747056E (sr)
SI (1) SI0747056T1 (sr)
TR (1) TR199701508T1 (sr)
WO (1) WO1996039141A1 (sr)
YU (1) YU34296A (sr)
ZA (1) ZA964681B (sr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2272345A1 (en) * 1996-11-22 1998-06-04 Akzo Nobel Nv Bmp-4 promoter and use thereof in screening of therapeutic agents for the prevention and/or treatment of osteoporosis
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
US6096764A (en) * 1997-08-21 2000-08-01 Eli Lilly And Company Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
US5393785A (en) * 1988-10-31 1995-02-28 Endorecherche, Inc. Therapeutic antiestrogens
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
DE4329344A1 (de) * 1993-08-27 1995-03-02 Schering Ag Progesteronantagonistisch- und antiöstrogen wirksame Verbindungen für die Behandlung des Leiomyomata uteri

Also Published As

Publication number Publication date
WO1996039141A1 (en) 1996-12-12
NO975560D0 (no) 1997-12-02
PT747056E (pt) 2000-05-31
AU696927B2 (en) 1998-09-24
IL118573A (en) 2000-01-31
CN1239429A (zh) 1999-12-22
ES2142545T3 (es) 2000-04-16
PL323941A1 (en) 1998-04-27
EA199800014A1 (ru) 1998-06-25
BR9608390A (pt) 1999-05-04
SI0747056T1 (en) 2000-06-30
IL118573A0 (en) 1996-10-16
ZA964681B (en) 1997-12-05
CO4700447A1 (es) 1998-12-29
DE69605600T2 (de) 2000-05-31
EP0747056B1 (en) 1999-12-15
EP0747056A2 (en) 1996-12-11
DK0747056T3 (da) 2000-05-01
ATE187643T1 (de) 2000-01-15
NO975560L (no) 1998-01-26
DE69605600D1 (de) 2000-01-20
AR003002A1 (es) 1998-05-27
EP0747056A3 (en) 1997-03-05
CZ383097A3 (cs) 1998-09-16
HUP9900854A3 (en) 2000-03-28
TR199701508T1 (xx) 1998-03-21
CA2223174A1 (en) 1996-12-12
HUP9900854A2 (hu) 1999-08-30
PE2298A1 (es) 1998-02-28
AR003134A1 (es) 1998-07-08
GR3032863T3 (en) 2000-07-31
KR19990022497A (ko) 1999-03-25
JP2001501907A (ja) 2001-02-13
AU5981696A (en) 1996-12-24

Similar Documents

Publication Publication Date Title
YU61595A (sh) Nova naftilna jedinjenja, njihovi intermedijeri farmaceutske kompozicije, i postupci za dobijanje tih jedinjenja
YU11496A (sh) Naftilna jedinjenja, njihove farmaceutske formulacije i intermedijari i postupak za njihovo dobijanje
KR950016745A (ko) 생리증상의 치료방법 및 이를 위한 조성물
BRPI0110955B8 (pt) derivados de tropano composição farmacêutica, uso dos mesmos na fabricação de um medicamento bem como processo para a preparação dos mesmos.
ES2141957T3 (es) Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales.
ATE202343T1 (de) Tricyclische derivate und ihre anwendung als arzneimittel
TW372969B (en) Pharmaceutical composition for minimizing bone loss
ATE240948T1 (de) Naphthyl- und dihydronaphthylverbindungen als arzneimittel
YU42397A (sh) Korišćenje raloksifena za pripremu leka
ATE253567T1 (de) Benzofuranverbindungen, präparate und verfahren
MY106401A (en) N-imidazolyl-and-n-imidazolymethyl-derivatives of substituted bicyclic compounds.
YU34296A (en) Use a compounds for medicament obtaining and pharmaceutical composition thereof
KR970705999A (ko) 타목시펜 및 타목시펜 유사체의 자궁향성 효과를 최소화시키는 방법 (a method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs)
ES2128701T3 (es) Derivados triciclicos y su uso en productos farmaceuticos.
MX9405111A (es) Nuevos derivados de (1-fenil-1-heterociclil)metanol y(1-fenil-1-heterociclil-metilamina).
DE69615657D1 (de) Antifungal fusacandine
YU11896A (sh) Benzotiofenska jedinjenja, intermedijeri, kompozicije koje ih sadrže
YU55495A (sh) Upotreba benzotiofena za dobijanje leka
AU2003247589A8 (en) Pentacyclic oxepines and derivatives thereof, process for their preparation and pharmaceutical compositions containing them